Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou Alphamab to Start China Trial of Biologic Infertility Treatment

publication date: Nov 3, 2016
Suzhou Alphamab will start a China Phase I trial for KN015, a biologic treatment for infertility. It is the first of Alphamab's novel biologic/biosimilar programs to reach the clinic. KN015 is a long-acting human follicle-stimulating hormone (FSH), used as part of an assisted reproductive therapy to develop multiple follicles in women. Unlike other currently available programs, KN015 is expected to require only a single injection, rather than daily injections, because of its enhanced half-life. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital